1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. Ca
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Wu L, Chang W, Zhao J, Yu Y, Tan X, Su T,
Zhao L, Huang S, Liu S and Cao G: Development of autoantibody
signatures as novel diagnostic biomarkers of non-small cell lung
cancer. Clin Cancer Res. 16:3760–3768. 2010.PubMed/NCBI
|
4
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
5
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Raymond E, Chaney SG, Taamma A and
Cvitkovic E: Oxaliplatin: A review of preclinical and clinical
studies. Ann Oncol. 9:1053–1071. 1998. View Article : Google Scholar : PubMed/NCBI
|
7
|
Borst P, Jonkers J and Rottenberg S: What
makes tumors multidrug resistant? Cell Cycle. 6:2782–2787. 2007.
View Article : Google Scholar : PubMed/NCBI
|
8
|
de Visser KE and Jonkers J: Towards
understanding the role of cancer-associated inflammation in
chemoresistance. Current Pharm Des. 15:1844–1853. 2009. View Article : Google Scholar
|
9
|
Solinas G, Germano G, Mantovani A and
Allavena P: Tumor-associated macrophages (TAM) as major players of
the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009.
View Article : Google Scholar : PubMed/NCBI
|
10
|
De Palma M and Lewis CE: Macrophage
regulation of tumor responses to anticancer therapies. Cancer Cell.
23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Amornsupuk K, Insawang T, Thuwajit P,
O-Charoenrat P, Eccles SA and Thuwajit C: Cancer-associated
fibroblasts induce high mobility group box 1 and contribute to
resistance to doxorubicin in breast cancer cells. BMC cancer.
14:9552014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Du Y, Su T, Zhao L, Tan X, Chang W, Zhang
H and Cao G: Associations of polymorphisms in DNA repair genes and
MDR1 gene with chemotherapy response and survival of non-small cell
lung cancer. PLoS One. 9:e998432014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
14
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Carus A, Gurney H, Gebski V, Harnett P,
Hui R, Kefford R, Wilcken N, Ladekarl M, von der Maase H and
Donskov F: Impact of baseline and nadir neutrophil index in
non-small cell lung cancer and ovarian cancer patients: Assessment
of chemotherapy for resolution of unfavourable neutrophilia. J
Transl Med. 11:1892013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zou ZY, Liu HL, Ning N, Li SY, Du XH and
Li R: Clinical significance of pre-operative neutrophil lymphocyte
ratio and platelet lymphocyte ratio as prognostic factors for
patients with colorectal cancer. Oncol Lett. 11:2241–2248. 2016.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Lai Q, Santa Castro E, Juri Rico JM,
Pinheiro RS and Lerut J: Neutrophil and platelet-to-lymphocyte
ratio as new predictors of dropout and recurrence after liver
transplantation for hepatocellular cancer. Transpl Int. 27:32–41.
2014. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim
KH and Kim HJ: Prognostic significance of neutrophil lymphocyte
ratio and platelet lymphocyte ratio in advanced gastric cancer
patients treated with FOLFOX chemotherapy. BMC Cancer. 13:3502013.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Feng JF, Huang Y and Chen QX: Preoperative
platelet lymphocyte ratio (PLR) is superior to neutrophil
lymphocyte ratio (NLR) as a predictive factor in patients with
esophageal squamous cell carcinoma. World J Surg Oncol. 12:582014.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Azab B, Shah N, Radbel J, Tan P, Bhatt V,
Vonfrolio S, Habeshy A, Picon A and Bloom S: Pretreatment
neutrophil/lymphocyte ratio is superior to platelet/lymphocyte
ratio as a predictor of long-term mortality in breast cancer
patients. Med Oncol. 30:4322013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Krenn-Pilko S, Langsenlehner U, Thurner
EM, Stojakovic T, Pichler M, Gerger A, Kapp KS and Langsenlehner T:
The elevated preoperative platelet-to-lymphocyte ratio predicts
poor prognosis in breast cancer patients. Br J Cancer.
110:2524–2530. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Asher V, Lee J, Innamaa A and Bali A:
Preoperative platelet lymphocyte ratio as an independent prognostic
marker in ovarian cancer. Clin Transl Oncol. 13:499–503. 2011.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Carus A, Ladekarl M, Hager H, Nedergaard
BS and Donskov F: Tumour-associated CD66b+ neutrophil count is an
independent prognostic factor for recurrence in localised cervical
cancer. Br J Cancer. 108:2116–2122. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Carus A, Ladekarl M, Hager H, Pilegaard H,
Nielsen PS and Donskov F: Tumor-associated neutrophils and
macrophages in non-small cell lung cancer: No immediate impact on
patient outcome. Lung Cancer. 81:130–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Liu H, Wu Y, Wang Z, Yao Y, Chen F, Zhang
H, Wang Y and Song Y: Pretreatment platelet-to-lymphocyte ratio
(PLR) as a predictor of response to first-line platinum-based
chemotherapy and prognosis for patients with non-small cell lung
cancer. J Thorac Dis. 5:783–789. 2013.PubMed/NCBI
|
29
|
DeNardo DG, Brennan DJ, Rexhepaj E,
Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD
and Junaid SA: Leukocyte complexity predicts breast cancer survival
and functionally regulates response to chemotherapy. Cancer Discov.
1:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Muccioli M and Benencia F: Toll-like
receptors in ovarian cancer as targets for immunotherapies. Front
Immunol. 5:3412014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Jinushi M and Komohara Y: Tumor-associated
macrophages as an emerging target against tumors: Creating a new
path from bench to bedside. Biochim Biophys Acta. 1855:123–130.
2015.PubMed/NCBI
|
32
|
Delitto D, Black BS, Sorenson HL, Knowlton
AE, Thomas RM, Sarosi GA, Moldawer LL, Behrns KE, Liu C, George TJ,
et al: The inflammatory milieu within the pancreatic cancer
microenvironment correlates with clinicopathologic parameters,
chemoresistance and survival. BMC Cancer. 15:7832015. View Article : Google Scholar : PubMed/NCBI
|
33
|
Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong
C, Su F and Song E: Pretreatment neutrophil-to-lymphocyte ratio is
correlated with response to neoadjuvant chemotherapy as an
independent prognostic indicator in breast cancer patients: A
retrospective study. BMC Cancer. 16:3202016. View Article : Google Scholar : PubMed/NCBI
|
34
|
Van Glabbeke M, Verweij J, Casali PG, Le
Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom
AT, Goldstein D, Sciot R, et al: Initial and late resistance to
imatinib in advanced gastrointestinal stromal tumors are predicted
by different prognostic factors: A european organisation for
research and treatment of cancer-italian sarcoma group-australasian
gastrointestinal trials group study. J Clin Oncol. 23:5795–5804.
2005. View Article : Google Scholar : PubMed/NCBI
|
35
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
36
|
Brower V: Biomarker studies abound for
early detection of lung cancer. J Natl Cancer Inst. 101:11–13.
2009. View Article : Google Scholar : PubMed/NCBI
|
37
|
Sun H, Hu P, Shen H, Dong W, Zhang T, Liu
Q and Du J: Albumin and neutrophil combined prognostic grade as a
new prognostic factor in non-small cell lung cancer: Results from a
large consecutive cohort. PLoS One. 10:e01446632015. View Article : Google Scholar : PubMed/NCBI
|
38
|
Kishida Y, Kawahara M, Teramukai S, Kubota
K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, et al:
Chemotherapy-induced neutropenia as a prognostic factor in advanced
non-small-cell lung cancer: Results from japan multinational trial
organization LC00-03. Br J Cancer. 101:1537–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
39
|
Schmidt H, Bastholt L, Geertsen P,
Christensen IJ, Larsen S, Gehl J and von der Maase H: Elevated
neutrophil and monocyte counts in peripheral blood are associated
with poor survival in patients with metastatic melanoma: A
prognostic model. Br J Cancer. 93:273–278. 2005. View Article : Google Scholar : PubMed/NCBI
|
40
|
Negrier S, Mejean A, Oudard S and Escudier
B: (Metastatic kidney cancer: New therapeutic approaches). Prog
Urol. 12:703–708. 2002.PubMed/NCBI
|
41
|
Paesmans M, Sculier JP, Lecomte J,
Thiriaux J, Libert P, Sergysels R, Bureau G, Dabouis G, Van Cutsem
O, Mommen P, et al: Prognostic factors for patients with small cell
lung carcinoma: Analysis of a series of 763 patients included in 4
consecutive prospective trials with a minimum follow-up of 5 years.
Cancer. 89:523–533. 2000. View Article : Google Scholar : PubMed/NCBI
|
42
|
Sato H, Tsubosa Y and Kawano T:
Correlation between the pretherapeutic neutrophil to lymphocyte
ratio and the pathologic response to neoadjuvant chemotherapy in
patients with advanced esophageal cancer. World J Surg. 36:617–622.
2012. View Article : Google Scholar : PubMed/NCBI
|
43
|
Eryilmaz MK, Mutlu H, Salim DK, Musri FY,
Tural D and Coskun HS: The neutrophil to lymphocyte ratio has a
high negative predictive value for pathologic complete response in
locally advanced breast cancer patients receiving neoadjuvant
chemotherapy. Asian Pac J Cancer Prev. 15:7737–7740. 2014.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Fridlender ZG, Sun J, Kim S, Kapoor V,
Cheng G, Ling L, Worthen GS and Albelda SM: Polarization of
tumor-associated neutrophil phenotype by TGF-beta: ‘N1’ versus ‘N2’
TAN. Cancer Cell. 16:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
45
|
Hu P, Wang G, Shen M, Zhang P, Zhang J, Du
J and Liu Q: Intratumoral polymorphonuclear granulocyte is
associated with poor prognosis in squamous esophageal cancer by
promoting epithelial-mesenchymal transition. Future Oncol.
11:771–783. 2015. View Article : Google Scholar : PubMed/NCBI
|
46
|
Hoshino H, Miyoshi N, Nagai K, Tomimaru Y,
Nagano H, Sekimoto M, Doki Y, Mori M and Ishii H:
Epithelial-mesenchymal transition with expression of SNAI1-induced
chemoresistance in colorectal cancer. Biochem Biophys Res Commun.
390:1061–1065. 2009. View Article : Google Scholar : PubMed/NCBI
|
47
|
Kurrey NK, Jalgaonkar SP, Joglekar AV,
Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA: Snail and slug
mediate radioresistance and chemoresistance by antagonizing
p53-mediated apoptosis and acquiring a stem-like phenotype in
ovarian cancer cells. Stem Cells. 27:2059–2068. 2009. View Article : Google Scholar : PubMed/NCBI
|
48
|
Canadas I, Rojo F, Taus Á, Arpí O,
Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M and Salido M:
Targeting epithelial-to-mesenchymal transition with Met inhibitors
reverts chemoresistance in small cell lung cancer. Clin Cancer Res.
20:938–950. 2014. View Article : Google Scholar : PubMed/NCBI
|
49
|
Dumitru CA, Lang S and Brandau S:
Modulation of neutrophil granulocytes in the tumor
microenvironment: Mechanisms and consequences for tumor
progression. Semin Cancer Biol. 23:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
50
|
Kelly MG, Alvero AB, Chen R, Silasi DA,
Abrahams VM, Chan S, Visintin I, Rutherford T and Mor G: TLR-4
signaling promotes tumor growth and paclitaxel chemoresistance in
ovarian cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI
|
51
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
52
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
53
|
Miao Y, Yan Q, Li S, Li B and Feng Y:
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are
predictive of chemotherapeutic response and prognosis in epithelial
ovarian cancer patients treated with platinum-based chemotherapy.
Cancer Biomark. 17:33–40. 2016. View Article : Google Scholar : PubMed/NCBI
|